{"protocolSection": {"identificationModule": {"nctId": "NCT02362646", "orgStudyIdInfo": {"id": "GCO 08-1078-0008"}, "secondaryIdInfos": [{"id": "2U01HL088942-07", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/2U01HL088942-07"}], "organization": {"fullName": "Icahn School of Medicine at Mount Sinai", "class": "OTHER"}, "briefTitle": "Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients", "officialTitle": "Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients"}, "statusModule": {"statusVerifiedDate": "2019-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-07"}, "primaryCompletionDateStruct": {"date": "2018-08-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-08-23", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-02-09", "studyFirstSubmitQcDate": "2015-02-12", "studyFirstPostDateStruct": {"date": "2015-02-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-11-07", "resultsFirstSubmitQcDate": "2019-11-07", "resultsFirstPostDateStruct": {"date": "2019-11-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-11-07", "lastUpdatePostDateStruct": {"date": "2019-11-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Annetine Gelijns", "investigatorTitle": "Chair, Department of Population Health Science & Policy; Edmond A. Guggenheim Professor of Health Policy; Co-Director, InCHOIR", "investigatorAffiliation": "Icahn School of Medicine at Mount Sinai"}, "leadSponsor": {"name": "Annetine Gelijns", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe. MPCs are normally present in human bone marrow and have been shown to increase the development of blood vessels and new heart muscle cells in the heart. In addition, this research is being done to test whether injecting the MPCs into the heart is effective in improving heart function.", "detailedDescription": "Intramyocardial injection of mesenchymal precursor cells (MPC) in patients with advanced heart failure who are treated with left ventricular assist device (LVAD) implantation may result in a renewable source of proliferating functional cardiomyocytes; induce development of capillaries and larger-size blood vessels to supply oxygen and nutrients to endogenous myocardium and newly-implanted cardiomyocytes; and release factors capable of paracrine signaling."}, "conditionsModule": {"conditions": ["Heart Failure", "Cardiomyopathy", "Ventricular Dysfunction"], "keywords": ["Heart Failure", "Left Ventricular Assist Device", "Heart Transplantation", "Cardiomyopathy, Destination Therapy", "Cell Therapy", "Bridge to Transplant"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 159, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MPC Intramyocardial Injection", "type": "EXPERIMENTAL", "description": "Intramyocardial injections of 150 million MPCs", "interventionNames": ["Biological: MPC Intramyocardial Injection"]}, {"label": "Control Solution", "type": "SHAM_COMPARATOR", "description": "Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO", "interventionNames": ["Drug: Control Solution"]}], "interventions": [{"type": "BIOLOGICAL", "name": "MPC Intramyocardial Injection", "description": "Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation", "armGroupLabels": ["MPC Intramyocardial Injection"], "otherNames": ["Mesenchymal Precursor Cell Injection", "RevascorTM"]}, {"type": "DRUG", "name": "Control Solution", "armGroupLabels": ["Control Solution"], "otherNames": ["50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO", "Cryoprotective media"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Temporary Weans From LVAD Support Tolerated", "description": "functional status, defined by the number of temporary weans from LVAD support tolerated over the 6 months post-randomization. A successful wean is the ability to tolerate temporary weaning from LVAD support for 30 minutes without sustained symptoms of worsening heart failure. Wean failures are defined as inability to tolerate the temporary wean for 30 minutes; death; or patient too unstable, in the judgment of the primary heart failure cardiologist, to tolerate the wean attempt.", "timeFrame": "up to 6 months"}, {"measure": "Number of Participants With Adverse Events", "description": "Safety as assessed by number of study intervention-related adverse events", "timeFrame": "up to 6 months"}], "secondaryOutcomes": [{"measure": "Physiologic Assessments", "description": "Echocardiographic assessments of the myocardial size and function by transthoracic echocardiography with LVAD at full support, and as tolerated following 6-Minute Walk Test (MWT) while weaned from LVAD support (for patients who tolerate wean from LVAD support for 30 minutes)", "timeFrame": "up to 12 months"}, {"measure": "Histopathological Assessments of Myocardial Tissue", "timeFrame": "up to 12 months"}, {"measure": "Overall Survival", "timeFrame": "up to 12 months"}, {"measure": "Change in Quality of Life (QoL)", "description": "Quality of life will be assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ), a widely used tool in heart failure populations, and the Short Form 12 (SF12), a widely used overall health status measure.", "timeFrame": "6 months and 12 months"}, {"measure": "Hopkins Verbal Learning Test", "description": "Cognitive performance will be assessed Hopkins Verbal Learning Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "timeFrame": "3 months and 12 months"}, {"measure": "Trailmaking Tests A and B", "description": "Cognitive performance will be assessed using Trailmaking Tests A and B. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "timeFrame": "3 months and 12 months"}, {"measure": "MCG Complex Figures", "description": "Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "timeFrame": "3 months and 12 months"}, {"measure": "Digit Span", "description": "Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "timeFrame": "3 months and 12 months"}, {"measure": "Digit Symbol Substitution Test", "description": "Cognitive performance will be assessed using the Digit Symbol Substitution Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "timeFrame": "3 months and 12 months"}, {"measure": "Controlled Oral Word Association", "description": "Cognitive performance will be assessed using the Controlled Oral Word Association. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "timeFrame": "3 months and 12 months"}, {"measure": "Length of Stay", "description": "Length of stay of index hospitalization", "timeFrame": "up to 12 months"}, {"measure": "Hospitalizations", "description": "Frequency and cause of readmissions", "timeFrame": "up to 12 months"}, {"measure": "Hospital Costs", "description": "Hospital resource use", "timeFrame": "up to 12 months"}, {"measure": "Functional Status", "description": "functional status, defined by the number of temporary weans from LVAD support tolerated", "timeFrame": "up to 12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent, inclusive of release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documentation\n* Age 18 years or older\n* If the subject or partner is of childbearing potential, he or she must be willing to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening and for a period of at least 16 weeks after procedure\n* Female subjects of childbearing potential must have a negative serum pregnancy test at screening\n* Admitted to the clinical center at the time of randomization\n* Clinical indication and accepted candidate for implantation of an FDA-approved (US sites only) or Health Canada-approved (Canadian sites only) implantable, non-pulsatile LVAD as a bridge to transplantation or for destination therapy.\n\nExclusion Criteria:\n\n* Planned percutaneous LVAD implantation\n* Anticipated requirement for biventricular mechanical support\n* Concomitant arrhythmia ablation at time of LVAD implantation\n\n  -- Planned aortic valve intervention for aortic insufficiency at the time of LVAD implantation\n* Cardiothoracic surgery within 30 days prior to randomization\n* Spontaneous myocardial infarction related to ischemia due to a primary coronary event such as unstable plaque rupture, erosion or dissection within 30 days prior to randomization\n* Prior cardiac transplantation, LV reduction surgery, or cardiomyoplasty\n* Acute reversible cause of heart failure (e.g. myocarditis, profound hypothyroidism)\n* Stroke within 30 days prior to randomization\n* Platelet count \\< 100,000/ul within 24 hours prior to randomization\n* Acute infectious process: acute bacterial, fungal, or viral disease OR acute exacerbation of chronic infectious disease such as hepatitis\n* Presence of \\>10% anti-HLA antibody titers with known specificity to MPC donor HLA antigens\n* A known hypersensitivity to dimethyl sulfoxide (DMSO), murine, and/or bovine products\n* History of a known active malignancy within the past 3 years except for localized prostate cancer, cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that has been definitively treated\n* Presence of human immunodeficiency virus (HIV)\n* Received investigational intervention within 30 days prior to randomization\n* Treatment and/or an incomplete follow-up treatment of any investigational cell based therapy within 6 months prior to randomization\n* Active participation in other research therapy for cardiovascular repair/regeneration\n* Prior recipient of stem precursor cell therapy for cardiac repair\n* Pregnant or breastfeeding at time of randomization.\n* History of known or suspected hypercoagulable state in the opinion of the investigator", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Patrick O'Gara, MD", "affiliation": "Brigham and Women's Hospital", "role": "STUDY_CHAIR"}, {"name": "Richard Weisel, MD", "affiliation": "Toronto General Hospital", "role": "STUDY_CHAIR"}], "locations": [{"facility": "University of Southern California", "city": "Los Angeles", "state": "California", "zip": "90033", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Stanford University School of Medicine", "city": "Stanford", "state": "California", "zip": "94305", "country": "United States", "geoPoint": {"lat": 37.42411, "lon": -122.16608}}, {"facility": "University of Maryland", "city": "Baltimore", "state": "Maryland", "zip": "21201", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "University of Michigan", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Henry Ford Hospital", "city": "Detroit", "state": "Michigan", "zip": "48202", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "Montefiore Einstein Heart Center", "city": "Bronx", "state": "New York", "zip": "10467", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Columbia University Medical Center", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Duke University", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Cleveland Clinic Foundation", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Ohio State University", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "University of Pittsburgh", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Baylor Research Institute", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "University of Utah", "city": "Salt Lake City", "state": "Utah", "zip": "84132", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "University of Virginia Health Systems", "city": "Charlottesville", "state": "Virginia", "zip": "22908", "country": "United States", "geoPoint": {"lat": 38.02931, "lon": -78.47668}}, {"facility": "University of Wisconsin School of Medicine and Public Health", "city": "Madison", "state": "Wisconsin", "zip": "53726", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "University of Alberta Hospital", "city": "Edmonton", "state": "Alberta", "zip": "T6G 2B7", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "Toronto General Hospital", "city": "Toronto", "state": "Ontario", "zip": "M5G 2C4", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Institut Universitaire de Cardiologie de Quebec (Hopital Laval)", "city": "Qu\u00e9bec City", "state": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}]}, "referencesModule": {"references": [{"pmid": "30912838", "type": "DERIVED", "citation": "Yau TM, Pagani FD, Mancini DM, Chang HL, Lala A, Woo YJ, Acker MA, Selzman CH, Soltesz EG, Kern JA, Maltais S, Charbonneau E, Pan S, Marks ME, Moquete EG, O'Sullivan KL, Taddei-Peters WC, McGowan LK, Green C, Rose EA, Jeffries N, Parides MK, Weisel RD, Miller MA, Hung J, O'Gara PT, Moskowitz AJ, Gelijns AC, Bagiella E, Milano CA; Cardiothoracic Surgical Trials Network. Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. JAMA. 2019 Mar 26;321(12):1176-1186. doi: 10.1001/jama.2019.2341. Erratum In: JAMA. 2019 Sep 3;322(9):895."}], "seeAlsoLinks": [{"label": "Cardiothoracic Surgical Network Website", "url": "http://www.ctsurgerynet.org/"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Screening started in 2014. First patient randomized in July 2015. Last patient randomized in August 2017.", "groups": [{"id": "FG000", "title": "MPC Intramyocardial Injection", "description": "MPC Intramyocardial Injection: Intramyocardial injection of 150 million mesenchymal precursor cells (MPCs) at the time of LVAD implantation"}, {"id": "FG001", "title": "Control Solution", "description": "Control Solution: Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "106"}, {"groupId": "FG001", "numSubjects": "53"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "29"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "24"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "received transplant", "reasons": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "14"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MPC Intramyocardial Injection", "description": "MPC Intramyocardial Injection: Intramyocardial injection of 150 million mesenchymal precursor cells (MPCs) at the time of LVAD implantation"}, {"id": "BG001", "title": "Control Solution", "description": "Control Solution: Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "106"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "159"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.5", "spread": "12.3"}, {"groupId": "BG001", "value": "56.9", "spread": "11.7"}, {"groupId": "BG002", "value": "56", "spread": "12.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "18"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "94"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "141"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "100"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "152"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "23"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "82"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "122"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Temporary Weans From LVAD Support Tolerated", "description": "functional status, defined by the number of temporary weans from LVAD support tolerated over the 6 months post-randomization. A successful wean is the ability to tolerate temporary weaning from LVAD support for 30 minutes without sustained symptoms of worsening heart failure. Wean failures are defined as inability to tolerate the temporary wean for 30 minutes; death; or patient too unstable, in the judgment of the primary heart failure cardiologist, to tolerate the wean attempt.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "number of weans", "timeFrame": "up to 6 months", "groups": [{"id": "OG000", "title": "MPC Intramyocardial Injection", "description": "MPC Intramyocardial Injection: Intramyocardial injection of 150 million mesenchymal precursor cells (MPCs) at the time of LVAD implantation"}, {"id": "OG001", "title": "Control Solution", "description": "Control Solution: Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.61", "spread": "0.41"}, {"groupId": "OG001", "value": "0.58", "spread": "0.45"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Adverse Events", "description": "Safety as assessed by number of study intervention-related adverse events", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "up to 6 months", "groups": [{"id": "OG000", "title": "MPC Intramyocardial Injection", "description": "Intramyocardial injections of 150 million MPCs\n\nMPC Intramyocardial Injection: Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation"}, {"id": "OG001", "title": "Control Solution", "description": "Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO\n\nControl Solution"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"title": "Serious AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "44"}]}]}, {"title": "Other than Serious AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "12"}]}]}]}, {"type": "SECONDARY", "title": "Physiologic Assessments", "description": "Echocardiographic assessments of the myocardial size and function by transthoracic echocardiography with LVAD at full support, and as tolerated following 6-Minute Walk Test (MWT) while weaned from LVAD support (for patients who tolerate wean from LVAD support for 30 minutes)", "reportingStatus": "NOT_POSTED", "timeFrame": "up to 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Histopathological Assessments of Myocardial Tissue", "reportingStatus": "NOT_POSTED", "timeFrame": "up to 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Overall Survival", "reportingStatus": "NOT_POSTED", "timeFrame": "up to 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Change in Quality of Life (QoL)", "description": "Quality of life will be assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ), a widely used tool in heart failure populations, and the Short Form 12 (SF12), a widely used overall health status measure.", "reportingStatus": "NOT_POSTED", "timeFrame": "6 months and 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Hopkins Verbal Learning Test", "description": "Cognitive performance will be assessed Hopkins Verbal Learning Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "reportingStatus": "NOT_POSTED", "timeFrame": "3 months and 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Trailmaking Tests A and B", "description": "Cognitive performance will be assessed using Trailmaking Tests A and B. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "reportingStatus": "NOT_POSTED", "timeFrame": "3 months and 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "MCG Complex Figures", "description": "Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "reportingStatus": "NOT_POSTED", "timeFrame": "3 months and 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Digit Span", "description": "Cognitive performance will be assessed using the MCG Complex Figures. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "reportingStatus": "NOT_POSTED", "timeFrame": "3 months and 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Digit Symbol Substitution Test", "description": "Cognitive performance will be assessed using the Digit Symbol Substitution Test. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "reportingStatus": "NOT_POSTED", "timeFrame": "3 months and 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Controlled Oral Word Association", "description": "Cognitive performance will be assessed using the Controlled Oral Word Association. Neurocognitive testing will be administered by clinical site personnel who have been trained and certified for test administration by the Neurocognitive Core lab personnel.", "reportingStatus": "NOT_POSTED", "timeFrame": "3 months and 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Length of Stay", "description": "Length of stay of index hospitalization", "reportingStatus": "NOT_POSTED", "timeFrame": "up to 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Hospitalizations", "description": "Frequency and cause of readmissions", "reportingStatus": "NOT_POSTED", "timeFrame": "up to 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Hospital Costs", "description": "Hospital resource use", "reportingStatus": "NOT_POSTED", "timeFrame": "up to 12 months", "denomUnitsSelected": "Participants"}, {"type": "SECONDARY", "title": "Functional Status", "description": "functional status, defined by the number of temporary weans from LVAD support tolerated", "reportingStatus": "NOT_POSTED", "timeFrame": "up to 12 months", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "6 months for adverse events 12 months for mortality", "description": "Trial specific protocol-defined adverse event", "eventGroups": [{"id": "EG000", "title": "MPC Intramyocardial Injection", "description": "Intramyocardial injections of 150 million MPCs\n\nMPC Intramyocardial Injection: Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation", "deathsNumAffected": 15, "deathsNumAtRisk": 106, "seriousNumAffected": 88, "seriousNumAtRisk": 106, "otherNumAffected": 33, "otherNumAtRisk": 106}, {"id": "EG001", "title": "Control Solution", "description": "Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO\n\nControl Solution", "deathsNumAffected": 8, "deathsNumAtRisk": 53, "seriousNumAffected": 41, "seriousNumAtRisk": 53, "otherNumAffected": 12, "otherNumAtRisk": 53}], "seriousEvents": [{"term": "Bleeding", "organSystem": "General disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 51, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 53}]}, {"term": "Sustained ventricular dysrhythmia requiring defibrillation or cardioversion", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 53}]}, {"term": "Sustained supraventricular dysrhythmia requiring drug treatment or cardioversion", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 53}]}, {"term": "Pump thrombus confirmed", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 53}]}, {"term": "Pump thrombus suspected", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 53}]}, {"term": "Nonpump thrombus related", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Minor device malfunction", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Hemolysis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 53}]}, {"term": "Localized nondevice infection", "organSystem": "Infections and infestations", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 53}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 53}]}, {"term": "Percutaneous site and/or pocket infection", "organSystem": "Infections and infestations", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 53}]}, {"term": "Toxic metabolic encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 53}]}, {"term": "Ischemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 53}]}, {"term": "Intracranial hemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Transient ischemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 53}]}, {"term": "Other neurological dysfunction", "organSystem": "Nervous system disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 53}]}, {"term": "Renal dysfunction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 53}]}, {"term": "Right heart failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 53}]}, {"term": "Potential Inflammatory Responses", "organSystem": "General disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Pericardial Fluid Collection", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 53}]}, {"term": "Vasodilatory State", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Hepatic Dysfunction", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 53}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 53}]}, {"term": "MI (Non-perioperative)", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Psychiatric Episode", "organSystem": "Psychiatric disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 53}]}, {"term": "Arterial Non-CNS Thromboembolism", "organSystem": "Vascular disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 53}]}, {"term": "Venous Thromboembolism Event", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 53}]}, {"term": "Wound Dehiscence", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 53}]}, {"term": "Pleural Effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 53}]}, {"term": "Sustained SVT dysrhytmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "CTCAE (unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Sustained supraventricular dysrhythmia requiring drug treatment or cardioversion", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 53}]}, {"term": "Localized nondevice infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 53}]}, {"term": "Pleural Effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 53}]}], "otherEvents": [{"term": "Sustained supraventricular dysrhythmia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Sustained supraventricular dysrhythmia requiring drug treatment or cardioversion", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 53}]}, {"term": "Localized nondevice infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 53}]}, {"term": "Pleural Effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 106}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 53}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Annetine Gelijns, PhD", "organization": "Icahn School of Medicine at Mount Sinai", "email": "annetine.gelijns@mssm.edu", "phone": "212-659-9567"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-08-15", "uploadDate": "2019-10-30T14:17", "filename": "Prot_SAP_000.pdf", "size": 1204643}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000009202", "term": "Cardiomyopathies"}, {"id": "D000018754", "term": "Ventricular Dysfunction"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M20824", "name": "Ventricular Dysfunction", "asFound": "Ventricular Dysfunction", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}